Xinhua news agency, beijing, 2 december: when the chinese institute for research printed the medicine box: china's pharmaceutical industry started accelerating the run
Xinhua journalist
“at the time when only imported medicines were available to treat lung cancer, innovative drugs produced in the country are now not only equally effective, but also more pro-people-friendly and patients have more choice.” mr. Zhang, who was carrying prescription drugs, was outraged outside the pharmacy at a sanchae hospital in shanghai. One of the pd-1 inhibitors in his hands, an innovative drug developed by chinese pharmaceutical companies themselves, has become a common drug for clinical treatment。
The pharmaceutical industry, driven by policy innovation, technological breakthroughs, and capital support, is undergoing a profound transformation, with more and more “china’s originals” moving from the market to the world, pushing china from the pharmaceutical power to the pharmaceutical power。
Innovative developments in the pharmaceutical industry require institutional guarantees。
The introduction of the reform of the drug review and approval system in my country is a long-standing battle known by industry as “medical supply side reform”. At the beginning of the reform process, structural contradictions such as the backlog of drug reviews, the high percentage of low-level imitation and insufficient incentives for research and development of innovative medicines severely constrained industrial development。
A series of policy dividends resulting from the reforms have continued to be released since the fourteenth five-year review, and the innovative dynamism of enterprises has been greatly stimulated by the gradual establishment of breakthrough treatment drugs, conditional approvals, priority review approvals and special approvals。
“at the heart of reform is the primacy of support for innovation.” the relevant head of the drug registration department of the national drug authority stated that by changing the definition of a new drug from “new china” to “new world”, the central focus was to push innovation to improve the quality of the drug industry from “image” to “original”, while bringing china's pharmaceutical industry into line with international standards to avoid duplication of research and development at low levels and to focus on the world's first drug。
The time taken to conduct clinical drug trial reviews in our country has now been reduced from 108 days in 2018 to 50 days in 2024, and beijing and shanghai pilot regions have further reduced the approval of clinical trial reviews of eligible innovative drugs to 30 days to make the market for innovative medicines easier。
Since the fourteenth five-year plan, our innovative drug research and development has achieved a double leap in size and quality, and the capacity for innovation at the source has continued to grow。
Recently, innovative medicines from zhejiang mai and biomedicine ltd. Have been officially declared overseas. The mt-001 capsule, developed by the company on its own initiative, is an innovative drug to fill the gap in the international treatment of cartiloma and the first new target species found by our scientists in the field, not only “new global” but also “new source”. “most of our past innovations have been followed, and we have now been able to achieve the best or even the best in some areas. The president of the company, yang jibin, said。
The optimization of health-care access mechanisms has allowed innovative medicines to move faster into ordinary homes。
Since the establishment of the national health insurance board in 2018, the health-care catalogue has become “one year at a time” and the time between the listing of innovative medicines and their incorporation into health care has been significantly reduced。
“a former import of anti-cancer drugs costs tens of thousands of dollars, which, when included in health insurance, is now much less expensive, combined with competition for domestically produced medicines.” ms. Lee, a lung cancer patient in shandong zinan, said that her use of innovative drugs, which had been negotiated through health insurance, had significantly reduced prices and had reached most of the country's hospitals, significantly increasing the availability of medicines。
At the end of 2024, the office of the secretary of state issued an opinion on the overall deepening of the regulatory reform of pharmaceutical medical devices for the high-quality development of the pharmaceutical industry, with further support from the review and approval mechanisms and the strengthening of intellectual property protection. Policies such as the early resolution mechanism for pharmaceutical patent disputes have come to the fore, allowing innovators to “grace”。
According to data from the national drug institute, since 2018, 265 innovative drugs have been approved, 68 by the end of november 2025, more than six times the annual level in 2018; 191 rare medicines, 478 children's medicines have been approved, and many varieties have filled clinical gaps。
As we stand at the crossroads of “145” and “155”, our pharmaceutical industry is shifting from “sizing-up” to “value creation”。
Zebutini in the bezican state defeated the international contest for ibdini as the best btk inhibitor of its kind, and the world's first “pd-1+vegf” bipolar antibodies developed by the comfortian biological research were shown to be more effective in their research against pablo. Today, more and more chinese drugs are emerging abroad。
“international recognition of chinese innovation medicines continues to rise.” president zhu fei peng, president of china's big medical corporation, said that in recent years, the internationalization of our pharmaceutical companies has been deepening, not only by authorizing cooperation in the expansion of overseas markets, but also by actively establishing research and development centres abroad so that domestically produced innovative medicines directly serve patients abroad。
The “fifty-five” plan proposes to support the development of innovative medicines and medical devices in the context of the deployment around “accelerating the construction of a healthy china”。
From the potential of laboratories to the precision of production lines, from the gradual replacement of domestic markets to accelerated integration into the global pharmaceutical industry, more effective and affordable chinese innovation will give new hope to patients in china and around the world。
